SCHEMBL29660409

SCHEMBL29660409

CCOc1ccc(-c2nc(C(=O)OC(C)(C)C)c(C(C)=O)s2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
KDM4E B2RXH2 3/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
ALDH1A1 P00352 1/20 0.46
PTPN11 Q06124 2/20 0.46
TRPM8 Q7Z2W7 5/20 0.42
TARBP2 Q15633 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HSP90AA1 P07900 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
HIF1A Q16665 1/20 0.41
NPC1 O15118 1/20 0.40
TP53 P04637 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ALPL P05186 1/20 0.40
ALPI P09923 1/20 0.40
CDC7 O00311 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29660334 0.88 TARBP2 (0.44) MAPTKDM4ERAB9ASMN1; SMN2ALDH1A1
SCHEMBL29660337 0.86 KDM4E (0.42) MAPTKDM4ERAB9ASMN1; SMN2ALDH1A1
SCHEMBL29660317 0.85 PTPN11 (0.44) MAPTKDM4ERAB9ASMN1; SMN2ALDH1A1
SCHEMBL29660324 0.85 MAPT (0.42) MAPTKDM4ERAB9ASMN1; SMN2ALDH1A1
SCHEMBL29660360 0.83 TARBP2 (0.41) MAPTKDM4ERAB9ASMN1; SMN2ALDH1A1
SCHEMBL29660340 0.83 MAPT (0.40) MAPTKDM4ERAB9ASMN1; SMN2ALDH1A1
SCHEMBL29660299 0.80 HSD17B10 (0.40) MAPTKDM4ERAB9ASMN1; SMN2ALDH1A1
SCHEMBL29660346 0.80 MAPT (0.42) MAPTKDM4ERAB9ASMN1; SMN2ALDH1A1
SCHEMBL29911091 0.79 MAPT (0.41) MAPTKDM4ERAB9ASMN1; SMN2ALDH1A1
SCHEMBL29660309 0.78 MAPT (0.43) MAPTKDM4ERAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220289698-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-09-15 US disclosed
EP-4003955-A1 INHIBITORS OF HUMAN ATGL Karl-Franzens-Universität Graz (AT) 2022-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289698-A1 INHIBITORS OF HUMAN ATGL LIPC, LIPG, PNLIP MAPT 2152/4885KDM4E 3614/4885RAB9A 3552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.